GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Non Operating Income

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Non Operating Income : $ Mil (TTM As of Dec. 2022)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Non Operating Income?

Non Operating Income is income or expense that comes from miscellaneous sources. CERo Therapeutics Holdings's Non Operating Income for the six months ended in Dec. 2022 was $0.00 Mil.


CERo Therapeutics Holdings Non Operating Income Historical Data

The historical data trend for CERo Therapeutics Holdings's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Non Operating Income Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
Non Operating Income
- -

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
Non Operating Income - -

CERo Therapeutics Holdings Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.


CERo Therapeutics Holdings Non Operating Income Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Non Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines